Key facts
- This page summarizes Vaseem Mahboob's Form 4 filing for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 29 Oct 2026, 18:46.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Options Exercise
Sale
Options Exercise
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
This reported transaction is a scheduled exercise and sale pursuant to a Rule 10b5-1 trading plan adopted on November 5, 2025.
Footnote F2
The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.0000 to $30.4300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
Footnote F3
The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.0100 to $30.9800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
Footnote F4
The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $30.3500 to $31.0400. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
Footnote F5
Includes 91,066 fully vested options as of the transaction date, with the remaining 33,125 options vesting in equal monthly installments through March 6, 2027.
Footnote F6
Includes 51,163 fully vested options as of the transaction date, with the remaining 33,125 options vesting in equal monthly installments through March 6, 2027.
Footnote F7
Includes 46,375 fully vested options as of the filing date, with the remaining 33,125 options vesting in equal monthly installments through March 6, 2027.